Annual SGA
$13.38 M
-$3.01 M-18.38%
December 31, 2023
Summary
- As of February 8, 2025, VYNE annual SGA is $13.38 million, with the most recent change of -$3.01 million (-18.38%) on December 31, 2023.
- During the last 3 years, VYNE annual SGA has fallen by -$76.17 million (-85.06%).
- VYNE annual SGA is now -85.06% below its all-time high of $89.54 million, reached on December 31, 2020.
Performance
VYNE SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$2.96 M
-$324.00 K-9.85%
September 30, 2024
Summary
- As of February 8, 2025, VYNE quarterly SGA is $2.96 million, with the most recent change of -$324.00 thousand (-9.85%) on September 30, 2024.
- Over the past year, VYNE quarterly SGA has dropped by -$324.00 thousand (-9.85%).
- VYNE quarterly SGA is now -88.80% below its all-time high of $26.46 million, reached on June 30, 2020.
Performance
VYNE Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$2.82 B
-$34.00 M-1.22%
September 30, 2024
Summary
- As of February 8, 2025, VYNE TTM SGA is -$2.82 billion, with the most recent change of -$34.00 million (-1.22%) on September 30, 2024.
- Over the past year, VYNE TTM SGA has dropped by -$2.83 billion (-20246.43%).
- VYNE TTM SGA is now -9247.70% below its all-time high of -$30.11 million.
Performance
VYNE TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
VYNE Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -18.4% | -9.8% | -10000.0% |
| 3 y3 years | -85.1% | -20.1% | -10000.0% |
| 5 y5 years | +9.8% | -20.1% | -10000.0% |
VYNE Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -34.1% | at low | -38.2% | at low | -14.4% | at low |
| 5 y | 5-year | -85.1% | at low | -88.8% | at low | -352.1% | at low |
| alltime | all time | -85.1% | +692.8% | -88.8% | +192.9% | -9247.7% | at low |
VYNE Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.96 M(-9.9%) | $13.91 M(-0.5%) |
| Jun 2024 | - | $3.29 M(-12.8%) | $13.97 M(+0.5%) |
| Mar 2024 | - | $3.77 M(-3.0%) | $13.90 M(+4.0%) |
| Dec 2023 | $13.38 M(-18.4%) | $3.88 M(+28.2%) | $13.38 M(+1.3%) |
| Sep 2023 | - | $3.03 M(-5.9%) | $13.20 M(-6.5%) |
| Jun 2023 | - | $3.22 M(-0.6%) | $14.13 M(-7.1%) |
| Mar 2023 | - | $3.24 M(-12.7%) | $15.21 M(-7.2%) |
| Dec 2022 | $16.39 M(-19.3%) | $3.71 M(-6.1%) | $16.39 M(-6.2%) |
| Sep 2022 | - | $3.95 M(-8.2%) | $17.47 M(-5.6%) |
| Jun 2022 | - | $4.30 M(-2.5%) | $18.50 M(-2.5%) |
| Mar 2022 | - | $4.42 M(-7.9%) | $18.98 M(-6.5%) |
| Dec 2021 | $20.30 M(-77.3%) | $4.79 M(-3.8%) | $20.30 M(-39.2%) |
| Sep 2021 | - | $4.98 M(+4.1%) | $33.41 M(-30.7%) |
| Jun 2021 | - | $4.79 M(-16.5%) | $48.19 M(-31.0%) |
| Mar 2021 | - | $5.73 M(-68.0%) | $69.86 M(-22.0%) |
| Dec 2020 | $89.54 M | $17.90 M(-9.4%) | $89.54 M(+9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $19.77 M(-25.3%) | $81.81 M(+22.4%) |
| Jun 2020 | - | $26.46 M(+4.1%) | $66.85 M(+51.4%) |
| Mar 2020 | - | $25.41 M(+149.9%) | $44.15 M(+96.4%) |
| Dec 2019 | $22.48 M(+84.5%) | $10.17 M(+111.7%) | $22.48 M(+43.4%) |
| Sep 2019 | - | $4.80 M(+27.8%) | $15.67 M(+12.7%) |
| Jun 2019 | - | $3.76 M(+0.3%) | $13.90 M(+5.1%) |
| Mar 2019 | - | $3.75 M(+11.4%) | $13.23 M(+8.6%) |
| Dec 2018 | $12.19 M(+135.8%) | $3.36 M(+10.8%) | $12.19 M(+15.7%) |
| Sep 2018 | - | $3.04 M(-1.8%) | $10.53 M(+20.6%) |
| Jun 2018 | - | $3.09 M(+14.6%) | $8.73 M(+27.4%) |
| Mar 2018 | - | $2.70 M(+58.1%) | $6.85 M(+32.6%) |
| Dec 2017 | $5.17 M(+37.8%) | $1.71 M(+38.0%) | $5.17 M(+8.6%) |
| Sep 2017 | - | $1.24 M(+1.8%) | $4.76 M(+35.1%) |
| Jun 2017 | - | $1.21 M(+20.0%) | $3.52 M(+52.6%) |
| Mar 2017 | - | $1.01 M(-22.0%) | $2.31 M(+78.0%) |
| Dec 2016 | $3.75 M(+122.3%) | $1.30 M | $1.30 M |
| Dec 2015 | $1.69 M | - | - |
FAQ
- What is VYNE Therapeutics annual SGA?
- What is the all time high annual SGA for VYNE Therapeutics?
- What is VYNE Therapeutics annual SGA year-on-year change?
- What is VYNE Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly SGA year-on-year change?
- What is VYNE Therapeutics TTM SGA?
- What is the all time high TTM SGA for VYNE Therapeutics?
- What is VYNE Therapeutics TTM SGA year-on-year change?
What is VYNE Therapeutics annual SGA?
The current annual SGA of VYNE is $13.38 M
What is the all time high annual SGA for VYNE Therapeutics?
VYNE Therapeutics all-time high annual SGA is $89.54 M
What is VYNE Therapeutics annual SGA year-on-year change?
Over the past year, VYNE annual SGA has changed by -$3.01 M (-18.38%)
What is VYNE Therapeutics quarterly SGA?
The current quarterly SGA of VYNE is $2.96 M
What is the all time high quarterly SGA for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly SGA is $26.46 M
What is VYNE Therapeutics quarterly SGA year-on-year change?
Over the past year, VYNE quarterly SGA has changed by -$324.00 K (-9.85%)
What is VYNE Therapeutics TTM SGA?
The current TTM SGA of VYNE is -$2.82 B
What is the all time high TTM SGA for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM SGA is -$30.11 M
What is VYNE Therapeutics TTM SGA year-on-year change?
Over the past year, VYNE TTM SGA has changed by -$2.83 B (-20246.43%)